ATAI LIFE SCIENCES BV EO1(9VC)

Description: Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

---

Keywords: Biopharmaceutical Schizophrenia Depression Gabaa Receptor Positive Allosteric Modulators Chloroarenes Post Traumatic Stress Disorder Opioid Use Disorder Anxiety Disorder Anxiolytics Cognitive Impairment Psychedelic Drug Mental Health Disorders Treatment Resistant Depression Ibogaine Treatment Of Opioid Use Disorder 5 Meo Dmt Treatment Of Post Traumatic Stress Disorder Benzoxazines Deuterated Etifoxine

---

Home Page: www.atai.life

Wallstrasse 16
Berlin, 10179
Germany
Phone: 49 89 2153 9035

---

Officers

Exchange: F

Country: DE : Germany

Currency: Euro (€)